Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $15,235.60 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 1,858 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $15,235.60. Following the transaction, the insider owned 328,795 shares of the company’s stock, valued at $2,696,119. The trade was a 0.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $9.01 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $6.23 and a 12 month high of $16.44. The firm has a fifty day simple moving average of $8.80 and a 200 day simple moving average of $10.22. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -6.17 and a beta of 0.93. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Chardan Capital restated a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Finally, William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.78.

Institutional Trading of Ocular Therapeutix

A number of large investors have recently added to or reduced their stakes in OCUL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Ocular Therapeutix by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 5,156 shares during the last quarter. Caxton Associates LLP acquired a new stake in Ocular Therapeutix in the first quarter valued at $248,000. Creative Planning lifted its stake in Ocular Therapeutix by 21.5% in the second quarter. Creative Planning now owns 21,410 shares of the biopharmaceutical company’s stock valued at $199,000 after acquiring an additional 3,791 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Ocular Therapeutix by 110.8% in the second quarter. JPMorgan Chase & Co. now owns 712,100 shares of the biopharmaceutical company’s stock valued at $6,608,000 after acquiring an additional 374,269 shares during the last quarter. Finally, Prudential Financial Inc. lifted its stake in Ocular Therapeutix by 57.9% in the second quarter. Prudential Financial Inc. now owns 18,700 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 6,855 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.